Literature DB >> 12461754

Delineation of the minimal region of loss at 13q14 in multiple myeloma.

Manal O Elnenaei1, Rifat A Hamoudi, John Swansbury, Alicja M Gruszka-Westwood, Vasantha Brito-Babapulle, Estella Matutes, Daniel Catovsky.   

Abstract

Previous studies have focused on the incidence and prognostic implications of 13q14 deletions in multiple myeloma (MM), but none has sought to delineate the minimal common deleted region (CDR). In an effort to do so, dual-color interphase fluorescence in situ hybridization (FISH) was applied on 82 myeloma cases, initially by use of three probes for 13q14 (RB1, D13S319, and D13S25). Deletions were detected in 29/82 (35.4%) cases, and all except one were monoallelic. Subsequently, contiguous YACs, PACs, and a BAC spanning the 13q14-q21 region were employed for deletion mapping in addition to a 13q telomere probe. Large deletions extending to the 13q34 region were found in 55% of the deleted cases, whereas an additional 13.8% showed loss of both 13q34 and 13q14 regions with retention of 13q21. A CDR of approximately 350 kb was identified at 13q14 with the proximal border approximately 120 kb centromeric from D13S319, encompassing an area rich in expressed sequence tagged sites and containing DLEU1, DLEU2, and RFP2 genes. Direct sequencing of the RFP2 gene revealed no mutations in six patients and four MM cell lines harboring deletions of the CDR. However, a role for RFP2 in the pathogenesis of MM cannot yet be excluded, given that alternative mechanisms such as haploinsufficiency remain possible. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12461754     DOI: 10.1002/gcc.10140

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  20 in total

1.  Dysregulation of miRNAs in AL amyloidosis.

Authors:  Liangping Weng; Brian H Spencer; Pamela T SoohHoo; Lawreen H Connors; Carl J O'Hara; David C Seldin
Journal:  Amyloid       Date:  2011-08-11       Impact factor: 7.141

Review 2.  The essential role of evasion from cell death in cancer.

Authors:  Gemma L Kelly; Andreas Strasser
Journal:  Adv Cancer Res       Date:  2011       Impact factor: 6.242

3.  The RBCC gene RFP2 (Leu5) encodes a novel transmembrane E3 ubiquitin ligase involved in ERAD.

Authors:  Mikael Lerner; Martin Corcoran; Diana Cepeda; Michael L Nielsen; Roman Zubarev; Fredrik Pontén; Mathias Uhlén; Sophia Hober; Dan Grandér; Olle Sangfelt
Journal:  Mol Biol Cell       Date:  2007-02-21       Impact factor: 4.138

4.  Conservation of miR-15a/16-1 and miR-15b/16-2 clusters.

Authors:  Junming Yue; Gabor Tigyi
Journal:  Mamm Genome       Date:  2009-12-16       Impact factor: 2.957

5.  Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region.

Authors:  Aybike Birerdinc; Elizabeth Nohelty; Andrey Marakhonov; Ganiraju Manyam; Ivan Panov; Stephanie Coon; Eugene Nikitin; Mikhail Skoblov; Vikas Chandhoke; Ancha Baranova
Journal:  Tumour Biol       Date:  2009-12-18

6.  Human RFP2 gene promoter: unique structure and unusual strength.

Authors:  Mikhail Skoblov; Konstantin Shakhbazov; Dmitry Oshchepkov; Dmitry Ivanov; Anna Guskova; Dmitry Ivanov; Petr Rubtsov; Vladimir Prasolov; Nick Yankovsky; Ancha Baranova
Journal:  Biochem Biophys Res Commun       Date:  2006-02-17       Impact factor: 3.575

7.  Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma.

Authors:  Julie O'Neal; Feng Gao; Anjum Hassan; Ryan Monahan; Samantha Barrios; Manfred W Kilimann; Ian Lee; Wee J Chng; Ravi Vij; Michael H Tomasson
Journal:  Exp Hematol       Date:  2009-02       Impact factor: 3.084

8.  Evaluation of 13q14 status in multiple myeloma by digital single nucleotide polymorphism technology.

Authors:  Katy Hanlon; Lorna W Harries; Sian Ellard; Claudius E Rudin
Journal:  J Mol Diagn       Date:  2009-07-30       Impact factor: 5.568

Review 9.  Role of miR-15/16 in CLL.

Authors:  Y Pekarsky; C M Croce
Journal:  Cell Death Differ       Date:  2014-06-27       Impact factor: 15.828

10.  TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.

Authors:  Moshe E Gatt; Kohichi Takada; Mala Mani; Mikael Lerner; Marjorie Pick; Teru Hideshima; Daniel E Carrasco; Alexei Protopopov; Elena Ivanova; Olle Sangfelt; Dan Grandér; Bart Barlogie; John D Shaughnessy; Kenneth C Anderson; Daniel R Carrasco
Journal:  Br J Haematol       Date:  2013-05-07       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.